1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Psoriasis Treatment Market
2.2. Global Psoriasis Treatment Market, By Drug Class, 2023 (US$ Million)
2.3. Global Psoriasis Treatment Market, By Type, 2023 (US$ Million)
2.4. Global Psoriasis Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Psoriasis Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Psoriasis Treatment Market Vendors
3.2. Strategies Adopted by Psoriasis Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Psoriasis Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Psoriasis Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Top 3 Countries
5.3.2. TNF Inhibitors
5.3.3. Vitamin D Analogues
5.3.4. Interleukin Blockers
5.3.5. Topical Corticosteroids
5.3.6. Others

6. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Plaque psoriasis
6.3.2. Guttate psoriasis
6.3.3. Flexural or inverse psoriasis
6.3.4. Psoriatic arthritis
6.3.5. Other


7. North America Psoriasis Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
7.4.Psoriasis Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.1.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.2.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.3.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)

8. UK and European Union Psoriasis Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
8.4.Psoriasis Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.1.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.2.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.3.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.4.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.5.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.6.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)

9. Asia Pacific Psoriasis Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
9.4.Psoriasis Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.1.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.2.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.3.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.4.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.5.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.6.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)

10. Latin America Psoriasis Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
10.4.Psoriasis Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.1.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.2.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.3.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)

11. Middle East and Africa Psoriasis Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
11.3. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
11.4.Psoriasis Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.1.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.2.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Psoriasis Treatment Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.3.2. Psoriasis Treatment Market: By Type, 2022-2032, USD (Million)

12. Company Profile
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Amgen Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. AstraZeneca
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Biogen
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Boehringer Ingelheim
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Celgene
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Eli Lilly and Company
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Johnson & Johnson
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. LEO Pharma A/S
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Merck & Co., Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Novartis AG
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Pfizer, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Stiefel Laboratories Inc. (GlaxoSmithKline plc)
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Sun Pharmaceutical Industries
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives